; (C) encourages competition in the marketplace; (D) assures that any covered pediatric cancer drugs that the Secretary distributes or orders to be distributed under section 4 are used to treat pediatric cancer patients; and (E) rewards manufacturing quality. (3) Required agreement terms Each agreement under this section between the Secretary and a manufacturer of a covered pediatric cancer drug shall include the following: (A) The identity and quantity of each covered pediatric cancer drug that the manufacturer agrees to hold in reserve supply. (B) A requirement that such quantities shall be in addition to the average levels of inventory for the relevant covered pediatric cancer drug held by the manufacturer during the previous year. (C) A provision to ensure that each drug held in reserve supply has an expiration date at least 1 year beyond the current date. (D) A provision to allow the manufacturer to sell and replace, through normal commercial channels, any drug in reserve supply in order to remain in compliance with the provision described in subparagraph (C). (E) A requirement that the covered pediatric cancer drugs in reserve supply may only be held at a location in the United States. (F) In the case of a covered pediatric cancer drug manufactured at an eligible source facility that is not located in the United States, the manufacturer of such drug may comply with subparagraph (E)— (i) by storing the drug at an establishment located in the United States that is— (I) registered under section 510 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360 ); and (II) under common ownership and control with the manufacturer